Related Experiment Videos
[Ondansetron--a new anesthesia relevant antiemetic?]
Anaesthesiologie Und Reanimation
|January 1, 1994
Summary
Ondansetron effectively manages chemotherapy-induced nausea and vomiting. Promising results suggest potential for preventing and treating postoperative nausea and vomiting, though its perioperative role requires further definition.
Area of Science:
- Pharmacology
- Anesthesiology
- Oncology
Context:
- Chemotherapy-induced nausea and vomiting (CINV) is a significant challenge.
- Postoperative nausea and vomiting (PONV) affects patient recovery.
- Selective serotonin-3-receptor antagonists offer a targeted therapeutic approach.
Purpose:
- To evaluate the efficacy and safety of ondansetron for CINV.
- To explore ondansetron's potential in preventing and treating PONV.
- To determine the definitive role of ondansetron in the perioperative setting.
Summary:
- Ondansetron, a selective serotonin-3-receptor antagonist, is effective against CINV.
- Initial studies show promising results for ondansetron in PONV treatment and prevention.
- Further research is needed to establish ondansetron's precise perioperative application.
Impact:
- Ondansetron offers a new therapeutic option for managing chemotherapy side effects.
- Potential for improved patient outcomes and reduced discomfort in the postoperative period.
- Defines the need for further clinical trials to solidify ondansetron's role in surgical care.